Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non‐Small Cell Lung Cancer by Mario Nagase, Sergey Aksenov, Hong Yan, James Dunyak, Nidal Al‐Huniti

Connect to this object online.

Population pharmacokinetics and exposure-response modeling for evinacumab in homozygous familial hypercholesterolemia by Xia Pu, Mark Sale, Feng Yang, Yi Zhang, John D. Davis, Nidal Al‐Huniti

Connect to this object online.

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities by Nidal Al‐Huniti, Yan Feng, Jingyu (Jerry), Zheng Lu, Mario Nagase, Diansong Zhou, Jennifer Sheng

Connect to this object online.

Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer by Jenny‐Hoa Nguyen, Daniel Epling, Nancy Dolphin, Anne Paccaly, Daniela Conrado, John D. Davis, Nidal Al‐Huniti

Connect to this object online.

Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach by Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph Ware, J. Greg Slatter, Nidal Al‐Huniti

Connect to this object online.

A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab by Masood Khaksar Toroghi, Jim Bosley, Lyn M. Powell, Yi Zhang, Feng Yang, Xia Pu, John D. Davis, Nidal Al‐Huniti

Connect to this object online.

A drug‐disease model for predicting survival in an Ebola outbreak by Masood Khaksar Toroghi, Nidal Al‐Huniti, John D. Davis, A. Thomas DiCioccio, Ronda Rippley, Alina Baum, Christos A. Kyratsous, Sumathi Sivapalasingam, Joel Kantrowitz, Mohamed A. Kamal

Connect to this object online.